Ortho Clinical Diagnostics to Report First Quarter 2022 Results on May 4, 2022

Rhea-AI Summary

Ortho Clinical Diagnostics (Nasdaq: OCDX) will announce its first quarter results for 2022 after market close on May 4, 2022. A conference call to discuss these results is scheduled for 4:30 PM ET the same day, accessible via the company's 'Investors' page on their website or by phone. Notably, there will be no Q&A session due to the pending merger with Quidel Corporation, first announced on December 23, 2021. Ortho is a leader in in vitro diagnostics, impacting over 800,000 patients daily with innovative diagnostic solutions.

RARITAN, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it will report results for its first quarter 2022 ended April 3, 2022, after the market close on Wednesday, May 4, 2022.

Ortho Clinical Diagnostics will hold a conference call the same day at 4:30 pm ET to discuss the results. Interested parties can access the call and accompanying presentation on the “Investors” portion of the Company’s website at https://ir.orthoclinicaldiagnostics.com/. Presentation materials will also be posted to the “Investors” portion of the website at the time of the call. Those unable to access the webcast may join the call via phone by dialing 833-362-0203 (domestic) or 914-987-7672 (international) and entering Conference ID number 7768083.

A replay of the conference call will be available a few hours after the event on the “Investors” portion of the Company’s website, under the “Events” section.

Due to the proposed combination with Quidel Corporation previously announced on December 23, 2021, which is subject to the satisfaction of customary closing conditions, there will be no opportunity to ask questions on the conference call.

About Ortho Clinical Diagnostics

Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) is one of the world’s largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care.

More than 800,000 patients across the world are impacted by Ortho’s tests each day. Because Every Test Is A Life™, Ortho provides hospitals, hospital networks, clinical laboratories and blood banks around the world with innovative technology and tools to ensure test results are fast, accurate, and reliable. Ortho's customized solutions enhance clinical outcomes, improve efficiency, overcome lab staffing challenges and reduce costs.

From launching the first product to determine Rh+ or Rh- blood type, developing the world’s first tests for the detection of antibodies against HIV and hepatitis C, introducing patented dry-slide technology and marketing the first U.S. Food and Drug Administration-authorized high-volume antibody and antigen tests for COVID-19, Ortho has been a pioneering leader in the IVD space for over 80 years.

The company is powered by Ortho Care^®, an award-winning, holistic service and support program that ensures best-in-class technical, field and remote service and inventory support to laboratories in more than 130 countries and territories around the globe.

For more information, visit Ortho’s website or social media channels: LinkedIn, Twitter, Facebook and YouTube.

Investor Contact:
IR@orthoclinicaldiagnostics.com

Media Contact:
media@orthoclinicaldiagnostics.com

FAQ

When will Ortho Clinical Diagnostics report its Q1 2022 results?

Ortho Clinical Diagnostics will report results for its first quarter 2022 on May 4, 2022, after market close.

What time is the conference call for Ortho Clinical Diagnostics Q1 results?

The conference call is scheduled for 4:30 PM ET on May 4, 2022.

How can I access the Ortho Clinical Diagnostics conference call?

You can access the call on the 'Investors' section of their website or by calling 833-362-0203 for domestic or 914-987-7672 for international access.

Will there be a Q&A session during the Ortho Clinical Diagnostics conference call?

No, there will be no opportunity for questions during the conference call due to the pending merger with Quidel Corporation.

What is the significance of the merger with Quidel Corporation for OCDX?

The merger with Quidel Corporation is significant as it reflects Ortho Clinical Diagnostics' growth strategy, which was announced on December 23, 2021.